Levosalbutamol 1.25 mg + Budesonide IP 0.5 mg is a combination respiratory formulation designed for the effective management of bronchial asthma and chronic obstructive pulmonary disease (COPD). Levosalbutamol is a selective β2-adrenergic receptor agonist that provides rapid bronchodilation by relaxing airway smooth muscles, helping relieve bronchospasm, wheezing, and shortness of breath. Budesonide is an inhaled corticosteroid that reduces airway inflammation, swelling, and mucus production, thereby preventing asthma exacerbations and improving long-term respiratory control. This dual-action therapy offers both immediate symptom relief and long-term anti-inflammatory control, making it suitable for patients requiring maintenance as well as acute bronchospasm management under medical supervision. It is commonly administered via nebulization or inhalation as prescribed by a healthcare professional.
